The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, ...

The Lupus Research Alliance applauds the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation for litifilimab (BIIB059) in clinical development by Biogen ...

Please provide your email address to receive an email when new articles are posted on . Patients with lupus skin disease had similar survival rates and flares as those without skin manifestations. Due ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed ...

In a new letter, published in the Journal of the European Academy of Dermatology and Venereology, members of the lupus community underscore the critical need to recognize the unique challenges of ...

Lupus erythematosus is a heterogeneous autoimmune disorder that frequently manifests with distinctive cutaneous involvement. The cutaneous lesions, which range from a malar rash to more indurated, ...

--VIB7734 potently depletedblood andtissue resident plasmacytoid dendritic cells, an important source of inflammatory mediators in autoimmune diseases-- -- Treatment with VIB7734 resulted in ...

Managing CV includes general measures to keep the patient as comfortable as possible until lesions resolve spontaneously. These include resting, protecting fragile skin from injury, and using ...

Actress, singer and makeup mogul Selena Gomez has been candid about her experience of living with lupus. Since 2015, Gomez has documented on social media and in interviews the effect the condition has ...

When people talk about “lupus,” they usually mean systemic lupus erythematosus (SLE), the most common type. But there are several other types and subtypes, some of which can overlap. Lupus is a ...